Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer

Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane (paclitaxel protein-bound; nab-paclitaxel and carboplatin) for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adult patients whose tumours display no EGFR or ALK genomic aberrations.

Phase 3 data submitted in support of the approval showed that the combo produced a median overall survival benefit of 18.6 months compared to 13.9 months with chemo alone in the intention-to-treat wild-type populati

read more

Original Article: Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer

More From BioPortfolio on "Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer"

• Related Companies
• Related Clinical Trials
• Related PubMed Entries
• Related Medications